Search
Foghorn Therapeutics Inc.
FHTXAdd to Watchlist
2.070USD
+0.020+0.98%
Close 11-13 16:00（ET）
122.94MMarket Cap
LossP/E TTM
Foghorn Therapeutics Inc. (FHTX) Stock Price Target & Forecast
Analyst Rating
Based on 10 analysts giving stock ratings to Foghorn Therapeutics Inc. in the past month.
Buy
3 Strong Buy
3 Buy
4 Hold
0 Sell
0 Strong Sell
Target Price
5.500USD+164.42%
FHTX Analyst Recommendation Trends
In the current month, FHTX has received 3 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. FHTX average Analyst price target in the last month is 5.500.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
3
5
5
5
5
5
5
5
3
5
5
5
5
5
5
5
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
10
10
10
10
10
10
10
FHTX Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, FHTX EPS is projected to reach -0.244 in FY2026Q4, following reported EPS of 0.801 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.30
-0.26
-0.24
-0.24
-0.26
Actual
-0.29
-0.10
0.80
--
--
Surprise
+6.29%
+60.21%
+433.77%
--
--
FAQs
What is Foghorn Therapeutics Inc.'s expected revenue for the next quarter?
Foghorn Therapeutics Inc.'s expected revenue is 2.20M.
What is Foghorn Therapeutics Inc.'s price target?
Analysts forecast that Foghorn Therapeutics Inc.'s price target is USD 5.50, with the highest forecast at USD 10.00 and the lowest forecast at USD 2.00.
How have Foghorn Therapeutics Inc.FHTX's recent earnings per share performed?
The market expectation was USD 0.80, while Foghorn Therapeutics Inc.FHTX's earnings per share (EPS) for the previous quarter was USD -0.10. EPS for the next quarter is expected at USD -0.24.
What is the analyst rating for Foghorn Therapeutics Inc.?
Based on the ratings of Foghorn Therapeutics Inc.'s stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.